New therapeutic approaches for the treatment of hypertriglyceridemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-04-22

AUTHORS

Ioanna Gouni-Berthold, Jonas Schwarz

ABSTRACT

Patients with hypertriglyceridemia (> 150 mg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (> 880 mg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega‑3 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor α (PPARα) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like 3 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein C-III and ANGPTL3 protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice. More... »

PAGES

220-227

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x

DOI

http://dx.doi.org/10.1007/s00059-022-05113-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147317491

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35451595


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiopoietin-Like Protein 3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiopoietin-like Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apolipoprotein C-III", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertriglyceridemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triglycerides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gouni-Berthold", 
        "givenName": "Ioanna", 
        "id": "sg:person.01341766537.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341766537.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str.\u00a062, 50937, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwarz", 
        "givenName": "Jonas", 
        "id": "sg:person.012166327420.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012166327420.59"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11883-020-00897-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134291419", 
          "https://doi.org/10.1007/s11883-020-00897-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-021-00919-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136818048", 
          "https://doi.org/10.1007/s11883-021-00919-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-021-01291-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137733674", 
          "https://doi.org/10.1186/s12933-021-01291-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11883-021-00914-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136301265", 
          "https://doi.org/10.1007/s11883-021-00914-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-021-01516-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138150105", 
          "https://doi.org/10.1007/s40265-021-01516-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-22", 
    "datePublishedReg": "2022-04-22", 
    "description": "Patients with hypertriglyceridemia (>\u202f150\u202fmg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (>\u202f880\u202fmg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega\u20113 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a\u00a0purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor\u00a0\u03b1 (PPAR\u03b1) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like\u00a03 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein\u00a0C-III and ANGPTL3\u00a0protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05113-x", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "treatment of hypertriglyceridemia", 
      "triglyceride levels", 
      "cardiovascular disease", 
      "selective peroxisome proliferator-activated receptor", 
      "peroxisome proliferator-activated receptor", 
      "top of statins", 
      "new drugs", 
      "atherosclerotic cardiovascular disease", 
      "normal triglyceride levels", 
      "proliferator-activated receptor", 
      "new therapeutic approaches", 
      "cardiovascular events", 
      "icosapent ethyl", 
      "available medications", 
      "risk factors", 
      "severe hypertriglyceridemia", 
      "binding antibodies", 
      "therapeutic approaches", 
      "hypertriglyceridemia", 
      "clinical practice", 
      "unmet need", 
      "apoC-III", 
      "larger study", 
      "eicosapentaenoic acid", 
      "promising target", 
      "longer duration", 
      "medications", 
      "statins", 
      "patients", 
      "treatment", 
      "disease", 
      "drugs", 
      "fatty acids", 
      "fibrates", 
      "pancreatitis", 
      "pemafibrate", 
      "diabetes", 
      "ANGPTL3", 
      "antibodies", 
      "apolipoproteins", 
      "receptors", 
      "levels", 
      "risk", 
      "inhibitors", 
      "duration", 
      "acid", 
      "siRNAs", 
      "antisense", 
      "modulator", 
      "target", 
      "factors", 
      "cases", 
      "development", 
      "protein", 
      "study", 
      "role", 
      "events", 
      "reduction", 
      "genetic data", 
      "need", 
      "practice", 
      "data", 
      "Japan", 
      "form", 
      "Germany", 
      "approach", 
      "formulation", 
      "ethyl", 
      "top"
    ], 
    "name": "New therapeutic approaches for the treatment of hypertriglyceridemia", 
    "pagination": "220-227", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147317491"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05113-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35451595"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05113-x", 
      "https://app.dimensions.ai/details/publication/pub.1147317491"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_948.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05113-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05113-x'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      107 URIs      94 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05113-x schema:about N1729667572dd412dbe7a95ec768ed4d5
2 N1dad88283f5f43cfa9d1ce3ff631f4d0
3 N3d7f202fa9bf4e1d9c31a5dca92f9a4b
4 N7020fb373ae44e8fac7306a50402e1d9
5 N918e51e431b3461fbc42046c8f6ff520
6 Ncad7f9abc9b244a4a5201c17b3aa7d07
7 Nd1ba2811844b486cac452905c9274954
8 Ne6fc207c08124f7a8458d52ded34d49e
9 anzsrc-for:11
10 anzsrc-for:1115
11 schema:author Nbb98e45ccc484e6a9be1d1865358b3e7
12 schema:citation sg:pub.10.1007/s11883-020-00897-x
13 sg:pub.10.1007/s11883-021-00914-7
14 sg:pub.10.1007/s11883-021-00919-2
15 sg:pub.10.1007/s40265-021-01516-y
16 sg:pub.10.1186/s12933-021-01291-w
17 schema:datePublished 2022-04-22
18 schema:datePublishedReg 2022-04-22
19 schema:description Patients with hypertriglyceridemia (> 150 mg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (> 880 mg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega‑3 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor α (PPARα) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like 3 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein C-III and ANGPTL3 protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf Ncc914acd48474735bcc8d0e38e4d9bd3
23 Ne8101ac86de6405fb9e06cabf6e115ec
24 sg:journal.1087175
25 schema:keywords ANGPTL3
26 Germany
27 Japan
28 acid
29 antibodies
30 antisense
31 apoC-III
32 apolipoproteins
33 approach
34 atherosclerotic cardiovascular disease
35 available medications
36 binding antibodies
37 cardiovascular disease
38 cardiovascular events
39 cases
40 clinical practice
41 data
42 development
43 diabetes
44 disease
45 drugs
46 duration
47 eicosapentaenoic acid
48 ethyl
49 events
50 factors
51 fatty acids
52 fibrates
53 form
54 formulation
55 genetic data
56 hypertriglyceridemia
57 icosapent ethyl
58 inhibitors
59 larger study
60 levels
61 longer duration
62 medications
63 modulator
64 need
65 new drugs
66 new therapeutic approaches
67 normal triglyceride levels
68 pancreatitis
69 patients
70 pemafibrate
71 peroxisome proliferator-activated receptor
72 practice
73 proliferator-activated receptor
74 promising target
75 protein
76 receptors
77 reduction
78 risk
79 risk factors
80 role
81 selective peroxisome proliferator-activated receptor
82 severe hypertriglyceridemia
83 siRNAs
84 statins
85 study
86 target
87 therapeutic approaches
88 top
89 top of statins
90 treatment
91 treatment of hypertriglyceridemia
92 triglyceride levels
93 unmet need
94 schema:name New therapeutic approaches for the treatment of hypertriglyceridemia
95 schema:pagination 220-227
96 schema:productId N1ab8ce47deaa4d5ba214f462522041e0
97 N4b28306f97694a89b33339871f66ca78
98 Nc802edca4ce949fa80baf915a2520f35
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147317491
100 https://doi.org/10.1007/s00059-022-05113-x
101 schema:sdDatePublished 2022-11-24T21:09
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N620689d21d8e426fa638b76f191fa5d7
104 schema:url https://doi.org/10.1007/s00059-022-05113-x
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N012ac7fa29f349c6a8cb815d09750678 rdf:first sg:person.012166327420.59
109 rdf:rest rdf:nil
110 N1729667572dd412dbe7a95ec768ed4d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Apolipoprotein C-III
112 rdf:type schema:DefinedTerm
113 N1ab8ce47deaa4d5ba214f462522041e0 schema:name pubmed_id
114 schema:value 35451595
115 rdf:type schema:PropertyValue
116 N1dad88283f5f43cfa9d1ce3ff631f4d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Hypertriglyceridemia
118 rdf:type schema:DefinedTerm
119 N3d7f202fa9bf4e1d9c31a5dca92f9a4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Angiopoietin-Like Protein 3
121 rdf:type schema:DefinedTerm
122 N4b28306f97694a89b33339871f66ca78 schema:name dimensions_id
123 schema:value pub.1147317491
124 rdf:type schema:PropertyValue
125 N620689d21d8e426fa638b76f191fa5d7 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N7020fb373ae44e8fac7306a50402e1d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Triglycerides
129 rdf:type schema:DefinedTerm
130 N918e51e431b3461fbc42046c8f6ff520 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
132 rdf:type schema:DefinedTerm
133 Nbb98e45ccc484e6a9be1d1865358b3e7 rdf:first sg:person.01341766537.07
134 rdf:rest N012ac7fa29f349c6a8cb815d09750678
135 Nc802edca4ce949fa80baf915a2520f35 schema:name doi
136 schema:value 10.1007/s00059-022-05113-x
137 rdf:type schema:PropertyValue
138 Ncad7f9abc9b244a4a5201c17b3aa7d07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cardiovascular Diseases
140 rdf:type schema:DefinedTerm
141 Ncc914acd48474735bcc8d0e38e4d9bd3 schema:volumeNumber 47
142 rdf:type schema:PublicationVolume
143 Nd1ba2811844b486cac452905c9274954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 Ne6fc207c08124f7a8458d52ded34d49e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Angiopoietin-like Proteins
148 rdf:type schema:DefinedTerm
149 Ne8101ac86de6405fb9e06cabf6e115ec schema:issueNumber 3
150 rdf:type schema:PublicationIssue
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
155 schema:name Pharmacology and Pharmaceutical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1087175 schema:issn 0340-9937
158 1615-6692
159 schema:name Herz
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.012166327420.59 schema:affiliation grid-institutes:grid.6190.e
163 schema:familyName Schwarz
164 schema:givenName Jonas
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012166327420.59
166 rdf:type schema:Person
167 sg:person.01341766537.07 schema:affiliation grid-institutes:grid.6190.e
168 schema:familyName Gouni-Berthold
169 schema:givenName Ioanna
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341766537.07
171 rdf:type schema:Person
172 sg:pub.10.1007/s11883-020-00897-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1134291419
173 https://doi.org/10.1007/s11883-020-00897-x
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/s11883-021-00914-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136301265
176 https://doi.org/10.1007/s11883-021-00914-7
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/s11883-021-00919-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136818048
179 https://doi.org/10.1007/s11883-021-00919-2
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/s40265-021-01516-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1138150105
182 https://doi.org/10.1007/s40265-021-01516-y
183 rdf:type schema:CreativeWork
184 sg:pub.10.1186/s12933-021-01291-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1137733674
185 https://doi.org/10.1186/s12933-021-01291-w
186 rdf:type schema:CreativeWork
187 grid-institutes:grid.6190.e schema:alternateName Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937, Köln, Germany
188 schema:name Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937, Köln, Germany
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...